Condition
Mucosal Leishmaniasis
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (3)
P 3 (1)
Trial Status
Recruiting2
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06550609Phase 2RecruitingPrimary
Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis with Inhaled Pentamidine Plus Oral Miltefosine
NCT04799236Phase 3RecruitingPrimary
Treatment of Mucosal Bolivian Leishmaniasis
NCT01050907Phase 2CompletedPrimary
Miltefosine to Treat Mucocutaneous Leishmaniasis
NCT01301937Phase 2UnknownPrimary
Low Antimonial Dosage in American Mucosal Leishmaniasis
Showing all 4 trials